Edition:
United Kingdom

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

26.06EUR
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
€26.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,980
52-wk High
€39.35
52-wk Low
€18.12

Latest Key Developments (Source: Significant Developments)

Mithra Announces New Agreement With GSP For Development Of Additional Injectable
Thursday, 18 Apr 2019 

April 18 (Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA ANNOUNCES NEW AGREEMENT WITH GSP FOR DEVELOPMENT OF AN ADDITIONAL INJECTABLE.AGREEMENT WITH GENERIC SPECIALTY PHARMA (GSP) FOR DEVELOPMENT AND SUPPLY OF A FIFTH HORMONAL INJECTABLE.  Full Article

Mithra Receives ODD From FDA For E4 In Neonatal Encephalopathy Treatment
Tuesday, 2 Apr 2019 

April 2 (Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR E4 IN NEONATAL ENCEPHALOPATHY TREATMENT.US FOOD AND DRUG ADMINISTRATION GRANTED E4 AN ODD FOR TREATMENT OF LIFE- THREATENING HYPOXIC ISCHEMIC ENCEPHALOPATHY (HIE).MITHRA CONTINUES ITS PRECLINICAL STUDIES IN HIE, A SEVERE PEDIATRIC SYNDROME THAT AFFECTS 30,000 NEWBORNS EACH YEAR IN EUROPE AND UNITED STATES.THIS NEW DESIGNATION EXPANDS E4'S BROAD POTENTIAL IN THERAPEUTIC AREAS BEYOND LEADING INDICATIONS IN WOMEN'S HEALTH.  Full Article

Mithra Pharmaceuticals Potential New Perimenopause Product Launch In 2023
Monday, 7 Jan 2019 

7/1/2019(Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA ANNOUNCED ON MONDAY POTENTIAL FOR NEW PERIMENOPAUSE PRODUCT CANDIDATE PERINESTA LAUNCH AS EARLY AS 2023.DONESTA PHASE III E4 MONOTHERAPY PATIENT RECRUITMENT ANTICIPATED TO START IN Q3 2019 PENDING APPROVALS.ONGOING GLOBAL PATENT FILINGS COULD PROTECT DONESTA AND PERINESTA IP ESTATE UNTIL 2039.  Full Article

Mithra Pharmaceuticals Announces Myring Update
Friday, 14 Dec 2018 

Dec 14 (Reuters) - MITHRA PHARMACEUTICALS SA ::LAUNCH OF MYRING™ EU PRODUCTION IN JANUARY 2019.FDA STATED THAT ADDITIONAL BIOEQUIVALENCE DATA WOULD BE REQUIRED TO SUPPORT THE ANDA, INCLUDING MANUFACTURE OF NEW TEST BATCHES.MITHRA'S US PARTNER MAYNE PHARMA RECEIVES COMPLETE RESPONSE LETTER FOR MYRING.MANUFACTURING OPERATIONS FOR MYRING™ ARE PLANNED TO BEGIN IN JANUARY 2019.INCREASED MANUFACTURING CAPACITY TO MEET MARKET DEMAND FOLLOWING LICENSING DEALS WITH MARKET LEADERS IN US, AUSTRIA, CZECH REPUBLIC, CHILE, DENMARK, RUSSIA, AUSTRALIA AND NEW ZEALAND.OVERALL 10 YEAR BUSINESS PLAN IS NOT EXPECTED TO BE IMPACTED AS COMPETITIVE LANDSCAPE HAS EVOLVED REFLECTING COMPLEXITY OF RING DEVELOPMENT.  Full Article

Mithra Pharmaceuticals Signs License and Supply Agreement In Australia And New Zealand
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - MITHRA PHARMACEUTICALS SA ::UNDER TERMS OF AGREEMENT, NEO HEALTH WILL HAVE RIGHTS TO SELL RING IN AUSTRALIA AND NEW ZEALAND .MITHRA SIGNS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT FOR VAGINAL CONTRACEPTIVE RING IN AUSTRALIA AND NEW ZEALAND.AGREEMENT FOLLOWS LICENSING DEALS FOR MYR ING™ WITH MARKET LEADERS IN US, AUSTRIA, CZECH REPUBLIC, CHILE, DENMARK, RUSSIA.PRODUCT TO BE MANUFACTURED AT MITHRA CDMO FACILITY IN BELGIUM.MITHRA GRANTS EXCLUSIVE 10-YEAR LICENSE FOR COMMERCIALIZATION OF VAGINAL CONTRACEPTION RING IN AUSTRALIA AND NEW ZEALAND TO NEO HEALTH.MITHRA WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT AND WILL BE ELIGIBLE TO RECEIVE MILESTONE PAYMENTS AND RECURRING REVENUES.MITHRA WILL EXCLUSIVELY MANUFACTURE PRODUCT AT ITS CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) FACILITY IN BELGIUM..  Full Article

Mithra Pharmaceuticals Signs Agreement For Commercialization Of Myring In Chile
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - MITHRA PHARMACEUTICALS SA ::SIGNS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT FOR COMMERCIALIZATION OF MYRING™ IN CHILE WITH LABORATORIO PASTEUR.WILL BE ELIGIBLE FOR UPFRONT AND MILESTONE PAYMENTS, MINIMAL ANNUAL QUANTITIES AND FURTHER SALES-RELATED ROYALTIES.WILL PRODUCE MYRING™ FOR THE CHILEAN MARKET AT ITS CDMO FACILITY IN BELGIUM.  Full Article

Mithra Pharmaceuticals H1 Net Loss For The Period Widens To 34.4‍​ Million Euros
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - MITHRA PHARMACEUTICALS SA ::H1 REVENUES EUR ‍​12.6 MILLION VERSUS EUR 12.7 MILLION YEAR AGO.H1 EBITDA LOSS EUR ‍​11.5 MILLION VERSUS LOSS OF EUR 23.2 MILLION YEAR AGO.H1 NET LOSS FOR THE PERIOD EUR 34.4‍​ MILLION VERSUS LOSS OF EUR 18.8 MILLION YEAR AGO.CASH AT JUNE 30 2018 OF EUR 85.8 MILLION, COMPARED TO EUR 36.2 MILLION AT END OF 2017.IN H1 RESEARCH AND DEVELOPMENT EXPENDITURE DECREASED BY 24 PERCENT TO EUR 19.4 MILLION.  Full Article

Mithra Pharmaceuticals And Orifarm Sign LSA For Vaginal Contraception Ring In Denmark
Thursday, 21 Jun 2018 

June 21 (Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA AND ORIFARM SIGN LSA FOR VAGINAL CONTRACEPTION RING IN DENMARK.VAGINAL RING SHALL BE MANUFACTURED AT MITHRA CDMO.AGREEMENT FOLLOWS MYRINGTM LICENSES1 CLOSED WITH MAYNE PHARMA, GYNIAL, ADAMED AND ALVOGEN FOR THE US, AUSTRIA, THE CZECH REPUBLIC AND RUSSIA, RESPECTIVELY.ORIFARM WILL HAVE RIGHTS TO SELL RING IN DENMARK MARKET WORTH APPROXIMATELY EUR 0.75 MILLION.IN ADDITION TO DOWNPAYMENT AND MILESTONE PAYMENTS, SEES ANNUAL REVENUES AFTER COMMERCIAL LAUNCH.  Full Article

Mithra Successfully Raises 77.5 Million Euros
Thursday, 31 May 2018 

May 31 (Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA SUCCESSFULLY RAISES EUR 77.5 MILLION.PRIVATE PLACEMENT OF 2,672,414 NEW SHARES THROUGH AN ACCELERATED BOOKBUILD OFFERING.PRICE OF EUR 29.00 PER SHARE, WHICH REPRESENTS A 10.2% DISCOUNT TO YESTERDAY'S CLOSING PRICE.TOTAL NUMBER OF ISSUED AND OUTSTANDING SHARES POST-TRANSACTION AT 37,639,495.  Full Article

Mithra Pharmaceuticals Launches Capital Increase
Wednesday, 30 May 2018 

May 30 (Reuters) - MITHRA PHARMACEUTICALS SA ::LAUNCHES CAPITAL INCREASE BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING.CAPITAL INCREASE OF APPROXIMATELY EUR 60 MILLION.POSSIBILITY TO INCREASE THE SIZE OF THE PRIVATE PLACEMENT TO UP TO 3,880,440 NEW SHARES IN TOTAL.ACCELERATED BOOKBUILD OFFERING WILL COMMENCE IMMEDIATELY.TRADING IN MITHRA SHARES ON EURONEXT BRUSSELS WILL BE SUSPENDED DURING BOOKBUILDING PERIOD.TRADING IN SHARES IS EXPECTED TO RESUME FOLLOWING PUBLICATION OF RESULTS OF PRIVATE PLACEMENT.KBC SECURITIES AND KEMPEN ARE ACTING AS JOINT BOOKRUNNERS.BELFIUS BANK ACTS AS LEAD MANAGER IN COOPERATION WITH KEPLER CHEUVREUX IN THE PRIVATE PLACEMENT.  Full Article

BRIEF-Mithra Pharmaceuticals Potential New Perimenopause Product Launch In 2023

* MITHRA ANNOUNCED ON MONDAY POTENTIAL FOR NEW PERIMENOPAUSE PRODUCT CANDIDATE PERINESTA LAUNCH AS EARLY AS 2023